Advertisement

Drug Safety

pp 1–15 | Cite as

Effectiveness of Risk Minimization Measures for Fentanyl Buccal Tablet (FENTORA) in Canada: A Mixed-Methods Evaluation Using Surveys, Medical Chart Records and Web Surveillance

  • Sigal KaplanEmail author
  • Aurore Bergamasco
  • Martin Sergerie
  • Anne-Marie Castilloux
  • Yola Moride
Original Research Article
  • 29 Downloads

Abstract

Background

Fentanyl buccal tablet (FBT), a potent opioid, was approved in Canada in 2013 for breakthrough pain in opioid-tolerant adult cancer patients. Additional risk minimization measures (aRMMs), consisting of communications to patients and healthcare providers (HCPs), were implemented from November 2014 through September 2015.

Objectives

The aim of this study was to assess the effectiveness of FBT aRMMs as measured by prescriber knowledge, understanding, and behavior regarding key safety concerns (off-label use, use in non-opioid-tolerant patients, misuse/abuse/diversion, and drug–drug interaction) and to evaluate illicit FBT use.

Methods

The study included three components: (1) a knowledge and understanding (KAU) survey of FBT prescribers conducted in two waves: November 2016–February 2017 and April–September 2018; (2) a retrospective prescription study of medical records of patients treated with FBT by a subgroup of prescribers from the KAU survey; and (3) Web surveillance of illicit FBT use in Canada using the search term FENTORA (May 2014–September 2018). The aRMMs were considered effective if the lower bound of the 95% confidence interval indicated that at least 65% of respondents met or partly met the knowledge objective for each key safety concern.

Results

KAU survey: Of 46 eligible HCPs, 97.8% met or partly met the knowledge objective on use in breakthrough pain cancer patients, 97.8% on use in opioid-tolerant patients, 89.1% on dose and titration, 100% on abuse/addiction, and 58.7% on drug–drug interaction. Retrospective prescription study: Of 22 FBT-treated patients identified from 14 HCPs, 45.5% had cancer, 50.0% recorded a breakthrough pain indication, and 36.4% reported opioid tolerance; however, only 13.6% of patients were prescribed FBT according to the approved indication. Web surveillance: Of 932 FBT posts in Canada, only 40 (4.3%) mentioned illicit use.

Conclusions

The aRMMs as measured by the prescriber KAU were effective for most key safety messages; however, not all key messages of the aRMMs were stringently followed in routine practice.

Notes

Acknowledgements

The authors would like to acknowledge Rukki Mirotznik for providing editorial support.

Compliance with Ethical Standards

Funding

This study was funded by Teva Canada Innovation.

Conflict of interest

Sigal Kaplan and Martin Sergerie are employees of Teva Pharmaceutical Industries Ltd and/or its affiliates. Aurore Bergamasco, Anne-Marie Castilloux and Yola Moride are employees of YOLARX Consultants, which received financial support from Teva Canada Innovation to conduct this research.

Disclaimer

The views expressed in this manuscript are those of the authors and do not necessarily reflect those of Teva.

Supplementary material

40264_2019_882_MOESM1_ESM.pdf (1.2 mb)
Supplementary material 1 (PDF 1262 kb)

References

  1. 1.
    Busse JW, Craigie S, Juurlink DN, Buckley DN, Wang L, Couban RJ, et al. Guideline for opioid therapy and chronic noncancer pain. CMAJ. 2017;189(18):E659-e66.CrossRefGoogle Scholar
  2. 2.
    Hauser W, Schug S, Furlan AD. The opioid epidemic and national guidelines for opioid therapy for chronic noncancer pain: a perspective from different continents. Pain Rep. 2017;2(3):e599.CrossRefGoogle Scholar
  3. 3.
    International Narcotics Control Board. Availability of internationally controlled drugs: ensuring adequate access for medical and scientific purposes. New York: United Nations; 2016. http://www.incb.org/documents/Publications/AnnualReports/AR2015/English/Supplement-AR15_availability_English.pdf. Accessed 13 May 2019.
  4. 4.
    Gomes T, Mastorakos A, Paterson JM, Sketris I, Caetano P, Greaves S, et al. Changes in the dispensing of opioid medications in Canada following the introduction of a tamper-deterrent formulation of long-acting oxycodone: a time series analysis. CMAJ Open. 2017;5(4):E800-e7.CrossRefGoogle Scholar
  5. 5.
    Belzak L, Halverson J. The opioid crisis in Canada: a national perspective. Health Promot Chronic Dis Prev Can. 2018;38(6):224–33.CrossRefGoogle Scholar
  6. 6.
    Canadian Centre on Substance Use and Addiction (CCSA). Joint statement of action to address the opioid crisis: a collective response. Annual report: 2016–2017. 2017. https://www.ccsa.ca/sites/default/files/2019-04/CCSA-Joint-Statement-of-Action-Opioid-Crisis-Annual-Report-2017-en.pdf. Accessed 23 May 2019.
  7. 7.
    Fischer B, Vojtila L, Rehm J. The ‘fentanyl epidemic’ in Canada - some cautionary observations focusing on opioid-related mortality. Prev Med. 2018;107:109–13.CrossRefGoogle Scholar
  8. 8.
    Grywacheski V, O’Connor S, Louie K. Opioid-related harms in Canada. Healthc Q. 2018;20(4):10–2.CrossRefGoogle Scholar
  9. 9.
    Madadi P, Hildebrandt D, Lauwers AE, Koren G. Characteristics of opioid-users whose death was related to opioid-toxicity: a population-based study in Ontario, Canada. PloS One. 2013;8(4):e60600.CrossRefGoogle Scholar
  10. 10.
    Martin TL, Woodall KL, McLellan BA. Fentanyl-related deaths in Ontario, Canada: toxicological findings and circumstances of death in 112 cases (2002–2004). J Anal Toxicol. 2006;30(8):603–10.CrossRefGoogle Scholar
  11. 11.
    National Opioid Use Guideline Group. Canadian guideline for safe and effective use of opioids for chronic non-cancer pain. 2010. http://nationalpaincentre.mcmaster.ca/documents/opioid_guideline_part_b_v5_6.pdf. Accessed 13 May 2019.
  12. 12.
    Canadian Institute for Health Information (CIHI). Opioid-related harms in Canada: chartbook. 2017. https://secure.cihi.ca/free_products/opioid-harms-chart-book-en.pdf. Accessed 5 Sept 2019.
  13. 13.
    Teva Canada Innovation. Fentora: product monograph. 2018. https://pdf.hres.ca/dpd_pm/00044144.PDF. Accessed 23 May 2019.
  14. 14.
    Brant JM, Rodgers BB, Gallagher E, Sundaramurthi T. Breakthrough cancer pain: a systematic review of pharmacologic management. Clin J Oncol Nurs. 2017;21(3 Suppl):71–80.CrossRefGoogle Scholar
  15. 15.
    Mercadante S. Breakthrough pain in cancer patients: prevalence, mechanisms and treatment options. Curr Opin Anesthesiol. 2015;28(5):559–64.CrossRefGoogle Scholar
  16. 16.
    Deandrea S, Corli O, Consonni D, Villani W, Greco MT, Apolone G. Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature. J Pain Symptom Manag. 2014;47(1):57–76.CrossRefGoogle Scholar
  17. 17.
    Caraceni A, Davies A, Poulain P, Cortes-Funes H, Panchal SJ, Fanelli G. Guidelines for the management of breakthrough pain in patients with cancer. J Natl Compr Cancer Netw. 2013;11(Suppl 1):S29–36.CrossRefGoogle Scholar
  18. 18.
    Health Canada. Submission of targeted risk management plans and follow-up commitments for prescription opioid-containing products—guidance for industry. 2018. https://www.canada.ca/en/health-canada/services/drugs-health-products/reports-publications/medeffect-canada/submission-targeted-rm-plans-commitments-prescription-opioid-containing-products-guidance-industry/document.html#a3.2.3.1. Accessed 9 Sept 2019.
  19. 19.
    Health Canada. New regulations to provide better information for patients on the safe use of opioid medications. 2018. https://www.canada.ca/en/health-canada/news/2018/05/new-regulations-to-provide-better-information-for-patients-on-the-safe-use-of-opioid-medications.html. Accessed 23 May 2019.
  20. 20.
    Osborne V, Layton D, Fogg C, Al-Shukri M, Shakir SA. Utilization of fentanyl buccal tablets in England: exploring off-label use reported in a cohort study. Eur J Pain. 2014;18(4):506–12.CrossRefGoogle Scholar
  21. 21.
    Gavrielov-Yusim N, Bidollari I, Kaplan S, Bartov N. Challenges of post-authorization safety studies: lessons learned and results of a French study of fentanyl buccal tablet. Pharmacoepidemiol Drug Saf. 2018;27(5):457–63.CrossRefGoogle Scholar
  22. 22.
    Dube PA, Vachon J, Sirois C, Roy E. Opioid prescribing and dispensing: experiences and perspectives from a survey of community pharmacists practising in the province of Quebec. Can Pharm J. 2018;151(6):408–18.CrossRefGoogle Scholar
  23. 23.
    Chang Y, Zhu KL, Florez ID, Cho SM, Zamir N, Toma A, et al. Attitudes toward the Canadian guideline for safe and effective use of opioids for chronic non-cancer pain: a qualitative study. J Opioid Manag. 2016;12(6):377–87.CrossRefGoogle Scholar
  24. 24.
    Rash JA, Buckley N, Busse JW, Campbell TS, Corace K, Cooper L, et al. Healthcare provider knowledge, attitudes, beliefs, and practices surrounding the prescription of opioids for chronic non-cancer pain in North America: protocol for a mixed-method systematic review. Syst Rev. 2018;7(1):189.CrossRefGoogle Scholar
  25. 25.
    Ashburn MA, Slevin KA, Messina J, Xie F. The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain. Anesth Analg. 2011;112(3):693–702.CrossRefGoogle Scholar
  26. 26.
    Farrar JT, Messina J, Xie F, Portenoy RK. A novel 12-week study, with three randomized, double-blind placebo-controlled periods to evaluate fentanyl buccal tablets for the relief of breakthrough pain in opioid-tolerant patients with noncancer-related chronic pain. Pain Med. 2010;11(9):1313–27.CrossRefGoogle Scholar
  27. 27.
    Fine PG, Messina J, Xie F, Rathmell J. Long-term safety and tolerability of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic pain: an 18-month study. J Pain Symptom Manag. 2010;40(5):747–60.CrossRefGoogle Scholar
  28. 28.
    Portenoy RK, Messina J, Xie F, Peppin J. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study. Curr Med Res Opin. 2007;23(1):223–33.CrossRefGoogle Scholar
  29. 29.
    Simpson DM, Messina J, Xie F, Hale M. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29(4):588–601.CrossRefGoogle Scholar
  30. 30.
    Webster LR, Messina J, Xie F, Nalamachu S. Effect of fentanyl buccal tablet on pain-related anxiety: a 4-week open-label study among opioid-tolerant patients with chronic and breakthrough pain. J Opioid Manag. 2011;7(4):297–308.CrossRefGoogle Scholar
  31. 31.
    Webster LR, Slevin KA, Narayana A, Earl CQ, Yang R. Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes. Pain Med. 2013;14(9):1332–45.CrossRefGoogle Scholar
  32. 32.
    Daeninck P, Gagnon B, Gallagher R, Henderson JD, Shir Y, Zimmermann C, et al. Canadian recommendations for the management of breakthrough cancer pain. Curr Oncol. 2016;23(2):96–108.CrossRefGoogle Scholar
  33. 33.
    Nkeng L, Cloutier AM, Craig C, Lelorier J, Moride Y. Impact of regulatory guidances and drug regulation on risk minimization interventions in drug safety: a systematic review. Drug Saf. 2012;35(7):535–46.CrossRefGoogle Scholar
  34. 34.
    Madison T, Arias A, DiSantostefano R, Gilsenan A, Matus D, Primatesta P, et al. Evaluating the effectiveness of additional risk minimization measures via surveys in Europe: challenges and recommendations. Endorsed by ISPE Board of Directors November 14, 2016. 2016. https://pharmacoepi.org/pub/f46953df-de69-31e7-8f74-725bd7fa685f. Accessed 13 May 2019.
  35. 35.
    Landsberg W, Al-Dakkak I, Coppin-Renz A, Geis U, Peters-Strickland T, van Heumen E, et al. Effectiveness evaluation of additional risk minimization measures for adolescent use of aripiprazole in the European Union: results from a post-authorization safety study. Drug Saf. 2018;41(8):797–806.CrossRefGoogle Scholar
  36. 36.
    Banerjee AK, Zomerdijk IM, Wooder S, Ingate S, Mayall SJ. Post-approval evaluation of effectiveness of risk minimisation: methods, challenges and interpretation. Drug Saf. 2014;37(1):33–42.CrossRefGoogle Scholar
  37. 37.
    Prieto L, Spooner A, Hidalgo-Simon A, Rubino A, Kurz X, Arlett P. Evaluation of the effectiveness of risk minimization measures. Pharmacoepidemiol Drug Saf. 2012;21(8):896–9.CrossRefGoogle Scholar
  38. 38.
    Food and Drug Administration (FDA). Survey methodologies to assess REMS goals that relate to knowledge—guidance for industry. 2019. https://www.fda.gov/media/119789/download. Accessed 27 June 2019.
  39. 39.
    European Medicines Agency (EMA). Guideline on good pharmacovigilance practices (GVP). Module XVI—Risk minimisation measures: selection of tools and effectiveness indicators (Rev 2). 2017. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-xvi-risk-minimisation-measures-selection-tools_en-3.pdf. Accessed 9 Sept 2019.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Teva Pharmaceutical Industries LtdNetanyaIsrael
  2. 2.YOLARX ConsultantsParisFrance
  3. 3.Teva Canada InnovationMontrealCanada
  4. 4.YOLARX ConsultantsMontrealCanada
  5. 5.Faculty of PharmacyUniversité de MontréalMontrealCanada
  6. 6.Rutgers, The State University of New JerseyNew BrunswickUSA

Personalised recommendations